-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Neutral on Maravai LifeSciences, Raises Price Target to $8

Benzinga·09/09/2026 17:52:30
语音播报
UBS analyst Dan Brennan maintains Maravai LifeSciences (NASDAQ:MRVI) with a Neutral and raises the price target from $2.5 to $8.